U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
Label updates include simplified twice-yearly echo monitoring for eligible CAMZYOS patients in the maintenance phase and expanded patient eligibility with reduced contraindications Updated U.S. label is supported by data including long-term clinical and real-world evidence which reinforce the strong safety profile of CAMZYOS PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #CAMZYOS—Bristol Myers Squibb (NYSE: BMY) today announced that the … [Read more…]